Resistance training attenuates inflammation and the progression of renal fibrosis in chronic renal disease
Carregando...
Citações na Scopus
26
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
SOUZA, Michel Kendy
NEVES, Rodrigo Vanerson Passos
ROSA, Thiago Santos
CENEDEZE, Marcos Antonio
BACURAU, Reury Frank Pereira
CAMARA, Niels Olsen Saraiva
MORAES, Milton Rocha
SILVA FILHO, Alvaro Pacheco e
Citação
LIFE SCIENCES, v.206, p.93-97, 2018
Resumo
Patients with chronic kidney disease (CKD) have progressive renal fibrosis, inflammation, and reduced muscle mass and strength. Resistance training (RT) has been suggested to mitigate the loss of muscle mass, of strength and the inflammation in CKD, but the mechanisms are unknown. The aim of this study was to evaluate the influence of RT on renal fibrosis, renal cytokine expression, creatine kinase levels, and muscle mass and strength in CKD rats. A CKD model was obtained by 5/6 nephrectomy (Nx). Fifteen 8-week-old male rats were divided into 3 groups: Sham (control), Nx SED (CKD sedentary) and Nx RT (CKD trained). The RT consisted of ladder climbing at 70% of the animal's maximal carrying capacity for 10 weeks. Muscle strength, creatine kinase levels, renal fibrosis and mRNA interleukin (IL)-4, IL-6 and IL-10 were analyzed after the RT protocol. There was significant improvement in the muscle strength and creatine kinase levels in the Nx RT group. Moreover, renal fibrosis and inflammation were attenuated, with increased IL-4 and IL-10 expression and reduced IL-6 expression in the Nx RT group compared with that in the Nx SED group. No difference in muscle mass was observed among the groups. In conclusion, RT was effective in reducing fibrosis and inflammation, in addition to increasing muscle strength and creatine kinase levels, in rats with CKD, independent of muscle mass.
Palavras-chave
Cytokines, Inflammation, Renal injury, Strength, Strength training
Referências
- Arias SCA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056215
- Barcellos FC, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-90
- Bruck K, 2015, CLIN KIDNEY J, V8, P647, DOI 10.1093/ckj/sfv082
- Correa-Costa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014298
- Ding Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020008
- Flahault A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156433
- Fleck C, 2006, EXP TOXICOL PATHOL, V57, P195, DOI 10.1016/j.etp.2005.09.005
- Grimm PC, 2003, J AM SOC NEPHROL, V14, P1662, DOI 10.1097/01.ASN.0000066143.02832.5E
- Olvera-Soto MG, 2016, J RENAL NUTR, V26, P53, DOI 10.1053/j.jrn.2015.06.006
- Hanatani S, 2014, J AM SOC NEPHROL, V25, P2800, DOI 10.1681/ASN.2013091025
- Hoffman JF, 2017, TOXICS, V5, DOI 10.3390/toxics5040025
- Kim HJ, 2015, EXP GERONTOL, V70, P11, DOI 10.1016/j.exger.2015.07.006
- Lancaster GI, 2014, TRENDS IMMUNOL, V35, P262, DOI 10.1016/j.it.2014.02.008
- Molsted S., 2014, BIOMED RES INT, V2014
- Moraes MR, 2012, J STRENGTH COND RES, V26, P1122, DOI 10.1519/JSC.0b013e31822dfc5e
- Passos CS, 2016, MED SCI SPORT EXER, V48, P1925, DOI 10.1249/MSS.0000000000000995
- Neves RVP, 2016, ARQ BRAS CARDIOL, V106, P201, DOI 10.5935/abc.20160019
- Peng CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037388
- Roshanravan B, 2017, AM J KIDNEY DIS, V69, P837, DOI 10.1053/j.ajkd.2017.01.051
- Sabatino A, 2017, J NEPHROL, V30, P743, DOI 10.1007/s40620-017-0435-5
- Miyagi MYS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108543
- de Araujo AJ, 2013, ARQ BRAS CARDIOL, V100, P339, DOI 10.5935/abc.20130051
- Stenvinkel P, 2016, NEPHROL DIAL TRANSPL, V31, P1070, DOI 10.1093/ndt/gfv122
- Tamaki M, 2015, ENDOCRINOLOGY, V156, P3638, DOI 10.1210/en.2015-1353
- Watson SL, 2018, J BONE MINER RES, V33, P211, DOI 10.1002/jbmr.3284
- Yazdi PG, 2013, INT J CLIN EXP MED, V6, P532
- Zhang LP, 2010, J AM SOC NEPHROL, V21, P419, DOI 10.1681/ASN.2009060571